EA201591579A1 - Способы лечения болезни крона при помощи анти-il-23 антитела - Google Patents

Способы лечения болезни крона при помощи анти-il-23 антитела

Info

Publication number
EA201591579A1
EA201591579A1 EA201591579A EA201591579A EA201591579A1 EA 201591579 A1 EA201591579 A1 EA 201591579A1 EA 201591579 A EA201591579 A EA 201591579A EA 201591579 A EA201591579 A EA 201591579A EA 201591579 A1 EA201591579 A1 EA 201591579A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
treatment
methods
disease
crohn
Prior art date
Application number
EA201591579A
Other languages
English (en)
Inventor
Вэй-Цзянь Пань
Уэйн Тсуцзи
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201591579A1 publication Critical patent/EA201591579A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Данное изобретение относится к продуктам и способам для лечения болезни Крона. Продукты относятся к антителам, которые ингибируют нативный человеческий IL-23, но при этом не затрагивают IL-12. Один пример описывает рандомизированное, двойное слепое плацебо-контролируемое исследование фазы 1 действия многократных нарастающих доз для оценки безопасности, переносимости, фармакокинетики и фармакодинамики анти-IL-23 антитела (AMG 139) для здоровых субъектов и субъектов с болезнью Крона в форме от легкой до тяжелой.
EA201591579A 2013-03-15 2014-02-25 Способы лечения болезни крона при помощи анти-il-23 антитела EA201591579A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15
PCT/US2014/018308 WO2014143540A1 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Publications (1)

Publication Number Publication Date
EA201591579A1 true EA201591579A1 (ru) 2016-01-29

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591579A EA201591579A1 (ru) 2013-03-15 2014-02-25 Способы лечения болезни крона при помощи анти-il-23 антитела

Country Status (17)

Country Link
US (5) US20160031983A1 (ru)
EP (2) EP2968486A1 (ru)
JP (4) JP2016516686A (ru)
KR (1) KR20150128859A (ru)
CN (1) CN105307675A (ru)
AP (1) AP2015008801A0 (ru)
AU (1) AU2014228553B2 (ru)
CA (1) CA2906384A1 (ru)
CL (1) CL2015002724A1 (ru)
EA (1) EA201591579A1 (ru)
HK (1) HK1220605A1 (ru)
IL (2) IL241343A0 (ru)
NZ (1) NZ712294A (ru)
PH (1) PH12015502133A1 (ru)
SG (2) SG11201507483PA (ru)
TN (1) TN2015000402A1 (ru)
WO (1) WO2014143540A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
JP6293120B2 (ja) 2012-05-03 2018-03-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ＩＬ−２３ｐ１９抗体
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3978530A1 (en) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
CA3019164A1 (en) * 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
US20180105588A1 (en) * 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
CN112689643A (zh) * 2018-07-13 2021-04-20 阿斯特捷利康合作创业有限责任公司 用布雷库单抗治疗溃疡性结肠炎
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
WO2021035129A1 (en) * 2019-08-21 2021-02-25 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
PL1896073T3 (pl) 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
PL1937721T3 (pl) 2005-08-25 2010-12-31 Lilly Co Eli Przeciwciała anty-IL23
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
SG10201402712QA (en) 2005-08-31 2014-08-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP2059534B1 (en) 2007-02-23 2012-04-25 Schering Corporation Engineered anti-il-23p19 antibodies
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2009225797A1 (en) * 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
US8263748B2 (en) 2008-08-27 2012-09-11 Schering Corporation Lyophilized formulations of engineered anti-IL-23p19 antibodies
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2523688T (pt) 2010-01-15 2018-01-05 Kirin Amgen Inc Formulação de anticorpo e regimes terapêuticos
NZ604415A (en) 2010-07-20 2014-10-31 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
NO2625199T3 (ru) * 2010-10-08 2018-04-21
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
RU2013136908A (ru) * 2011-01-07 2015-02-20 Эббви Инк. Антитела kil-12/il-23 и их применение

Also Published As

Publication number Publication date
CL2015002724A1 (es) 2016-03-28
EP3693007A1 (en) 2020-08-12
JP2016516686A (ja) 2016-06-09
AP2015008801A0 (en) 2015-10-31
IL241343A0 (en) 2015-11-30
CA2906384A1 (en) 2014-09-18
SG10201805015TA (en) 2018-07-30
AU2014228553A1 (en) 2015-10-08
CN105307675A (zh) 2016-02-03
NZ712294A (en) 2020-04-24
IL275092A (en) 2020-07-30
HK1220605A1 (zh) 2017-05-12
US20180327490A1 (en) 2018-11-15
EP2968486A1 (en) 2016-01-20
KR20150128859A (ko) 2015-11-18
JP2023012516A (ja) 2023-01-25
US20200017581A1 (en) 2020-01-16
US20170218062A1 (en) 2017-08-03
US20160031983A1 (en) 2016-02-04
JP2021107397A (ja) 2021-07-29
WO2014143540A1 (en) 2014-09-18
JP2020073470A (ja) 2020-05-14
US20200283517A1 (en) 2020-09-10
TN2015000402A1 (fr) 2017-01-03
PH12015502133A1 (en) 2016-01-25
SG11201507483PA (en) 2015-10-29
AU2014228553B2 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
EA201591579A1 (ru) Способы лечения болезни крона при помощи анти-il-23 антитела
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
EA201591581A1 (ru) Способы лечения псориаза при помощи анти-il-23 антитела
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112017012381A2 (pt) imunoterapia para doença angiogênica
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов
MD20180049A2 (ru) Фармацевтическая композиция
MX2017013879A (es) Composiciones que comprenden anakinra.
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен
EA202091619A3 (ru) Антитела против tigit